The stock price of Teva Pharmaceuticals rose 3.5% before the US listing, after the company's immune-disorder drugs reached a major end in mid-term trials.

Zhitongcaijing · 3d ago
The stock price of Teva Pharmaceuticals rose 3.5% before the US listing, after the company's immune-disorder drugs reached a major end in mid-term trials.